Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Z 360

Drug Profile

Z 360

Alternative Names: Z-360

Latest Information Update: 12 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zeria
  • Class Antineoplastics; Antiulcers; Benzodiazepines; Benzoic acids; Gastric antisecretories; Urea compounds
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Discontinued Peptic ulcer

Most Recent Events

  • 31 Jul 2019 Phase II development is ongoing for Pancreatic cancer (Combination therapy, Metastatic disease) in Japan, South Korea and Taiwan
  • 01 Mar 2017 Zeria completes a phase II trial in Pancreatic cancer (Metastatic disease, Combination therapy) in Japan, South Korea & Taiwan (NCT02117258)
  • 21 Sep 2015 No recent reports on development identified - Phase-I/II for Pancreatic cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top